{"article_id": "ABT_q3_2021.txt", "article": ["ongoing earnings per share were $ 1.40 , reflecting nearly 45 % growth compared to last year and sales increased more than 22 % on an organic basis .", "excluding covid testing - related sales , which totaled $ 1.9 billion in the quarter , organic sales increased 12 % versus last year .", "this has been a consistent theme throughout the pandemic , as evidenced by an increase in total company sales , excluding covid tests , of 11 % on an organic basis through the first nine months of this year compared to our 2019 pre-pandemic baseline , which highlights that our growth is real and not simply a function of easy comps versus last year .", "as a result of our strong performance and outlook , today , we increased our full year adjusted earnings per share guidance range now at $ 5 to $ 5.10 , which reflects nearly 40 % growth compared to last year .", "and i 'll start with nutrition , where sales increased 9 % compared to last year .", "in pediatric nutrition , sales grew over 8.5 % in the quarter , led by strong growth in the us from continued share gains in our infant formula and toddler portfolio .", "in adult nutrition , sales grew over 9 % in the quarter , including mid-teens growth internationally , as we continue to see strong demand for our ensure and glucerna brands , including new users entering these categories and existing customers increasing their usage .", "sales increased more than 45 % overall and 12.5 % , excluding covid testing - related sales .", "in total , during the quarter , we sold more than 225 million covid tests globally and have now shipped over 1 billion tests since the start of the pandemic .", "abbott has established a global leadership position in rapid testing , including a supply capacity of more than 100 million tests per month .", "moving to established pharmaceuticals , where sales grew more than 15 % , driven by strong execution and a steady cadence of new product introductions .", "strong sales performance in the quarter was broad - based across several countries , including double - digit growth in china , russia and india , which led to overall sales growth of 18 % in our key emerging markets .", "and lastly , i 'll cover medical devices , where sales grew 13 % in the quarter compared to last year and more than 16 % compared to pre-pandemic sales in the third quarter of 2019 .", "after adjusting for this impact , cardiomems demonstrated a 28 % reduction in heart failure hospitalizations .", "and i 'll wrap up with diabetes care , where strong growth was led by freestyle libre sales of nearly $ 1 billion .", "during the quarter , we added over 200,000 new users , bringing the total global user base for libre to well over 3.5 million users .", "and based on the strength of our performance and outlook , we 're raising our earnings per share guidance for the year , which now reflects growth of nearly 40 % compared to last year .", "sales for the third quarter increased 22.4 % on an organic basis , which was led by strong performance across all of our businesses , you along with global covid testing - related sales of $ 1.9 billion in the quarter .", "excluding covid testing - related sales , organic sales growth was 12.1 % versus last year and 11.7 % compared to the third quarter of 2019 .", "foreign exchange had a favorable year - over - year impact of 1 % on third quarter sales , resulting in total reported sales growth of 23.4 % in the quarter .", "regarding other aspects of the p&l for the quarter , the adjusted gross margin ratio was 58.8 % of sales , adjusted r&d investment was 6 % of sales and adjusted sg&a expense was 25 % of sales .", "our third quarter adjusted tax rate was 15.5 % , which reflects an adjustment to align our year - to - date tax rate with our revised full year effective tax rate forecast of 15 % .", "we forecast $ 1 billion to $ 1.4 billion of covid testing - related sales and forecast organic sales growth , excluding covid testing - related sales , in the low double - digits versus last year .", "and based on current rates , we would expect exchange to have an unfavorable impact of around one - half of 1 % on our fourth quarter reported sales ."], "summary_gold": "abbott sold more than 225 mln covid - 19 tests globally in q3 .<q>compname says company sold more than 225 million covid tests globally in third quarter .<q>compname says co has supply capacity of more than 100 million tests per month .<q>abbott forecasts $ 1 billion to $ 1.4 billion of covid testing - related sales in q4 .", "summary_pred": "after adjusting for this impact , cardiomems demonstrated a 28 % reduction in heart failure hospitalizations .<q>excluding covid testing - related sales , organic sales growth was 12.1 % versus last year and 11.7 % compared to the third quarter of 2019 .<q>foreign exchange had a favorable year - over - year impact of 1 % on third quarter sales , resulting in total reported sales growth of 23.4 % in the quarter .<q>and i 'll wrap up with diabetes care , where strong growth was led by freestyle libre sales of nearly $ 1 billion .<q>in total , during the quarter , we sold more than 225 million covid tests globally and have now shipped over 1 billion tests since the start of the pandemic .<q>our third quarter adjusted tax rate was 15.5 % , which reflects an adjustment to align our year - to - date tax rate with our revised full year effective tax rate forecast of 15 % .<q>moving to established pharmaceuticals , where sales grew more than 15 % , driven by strong execution and a steady cadence of new product introductions .<q>abbott has established a global leadership position in rapid testing , including a supply capacity of more than 100 million tests per month .", "len_article": 24, "len_summary_gold": 4, "len_summary_pred": 8, "len_sent_scores": 24}